Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Venture Funding Fell In 2012

by Melody M. Bomgardner
January 28, 2013 | A version of this story appeared in Volume 91, Issue 4

The prospect of federal government belt-tightening dampened venture capitalists’ enthusiasm for investing in new biotechnology and cleantech start-ups in 2012, according to the latest MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association. Investments in biotech companies declined 15% compared with 2011 to $4.1 billion, and the number of deals stayed flat. Tighter reimbursements from Medicare, along with lengthy and complicated FDA approval procedures, suppressed investment, says NVCA President Mark G. Heesen. Similarly, cleantech investors began moving toward more capital-efficient deals that are less dependent on government support. The sector saw investment drop 28% in 2012, with a corresponding 23% decline in deal volume. The fourth quarter was particularly weak as cleantech backing sank 36% from the third quarter. Brand-new start-ups in all sectors had a difficult time getting investors to part with funds; seed-stage funding decreased 31% in 2012. “As the number of new funds being raised continues to shrink, venture capitalists are being more discriminating with where they’re willing to place new bets,” explains Tracy T. Lefteroff, global managing partner at PwC.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.